Seattle Genetics Inc. said ladiratuzumab vedotin was well-tolerated in an ongoing phase 1 trial with metastatic triple negative breast cancer patients.
The study, conducted in 81 patients who had received prior systemic metastatic therapies, recorded a median progression-free survival of 11 weeks. Meanwhile, the median duration of response was 13.3 weeks.
Seattle Genetics reported a 25% objective response rate and 28% clinical benefit rate for 60 efficacy-evaluable patients.
The side effects in the trial included peripheral neuropathy, neutropenia and anemia.